Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
AC Immune SA - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ACIU
Nasdaq
8731
https://www.acimmune.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for AC Immune SA
Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance
- Jan 27th, 2023 2:57 pm
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
- Jan 26th, 2023 12:00 pm
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
- Jan 18th, 2023 12:00 pm
AC Immune SA's (NASDAQ:ACIU) largest shareholders are private equity firms with 39% ownership, individual investors own 29%
- Jan 7th, 2023 1:45 pm
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
- Nov 30th, 2022 12:00 pm
Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?
- Nov 25th, 2022 12:17 pm
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
- Nov 23rd, 2022 12:30 pm
AC Immune to Present at the Jefferies London Healthcare Conference
- Nov 8th, 2022 12:58 pm
Shareholders in AC Immune (NASDAQ:ACIU) are in the red if they invested five years ago
- Oct 29th, 2022 12:06 pm
AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates
- Oct 28th, 2022 1:25 pm
AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
- Oct 28th, 2022 12:00 pm
AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome
- Oct 4th, 2022 12:36 pm
AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer’s Disease
- Sep 26th, 2022 11:30 am
AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent
- Sep 1st, 2022 12:00 pm
AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer’s and Parkinson’s Diseases
- Aug 24th, 2022 8:05 pm
AC Immune to Host Key Opinion Leader Webinar on Vaccinations to Treat and Prevent Alzheimer’s and Parkinson’s Diseases
- Aug 11th, 2022 11:30 am
Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC
- Aug 2nd, 2022 3:00 pm
What Type Of Shareholders Own The Most Number of AC Immune SA (NASDAQ:ACIU) Shares?
- Jul 31st, 2022 12:12 pm
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
- Jul 28th, 2022 12:45 pm
AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update
- Jul 28th, 2022 11:30 am
Scroll